Literature DB >> 8885147

Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.

B E Fischer1, G Kramer, A Mitterer, L Grillberger, M Reiter, W Mundt, F Dorner, J Eibl.   

Abstract

The smallest circulating von Willebrand factor (vWF) molecule is a dimer composed of two identical subunits containing binding sites for heparin, collagen, platelet glycoproteins and coagulation factor VIII (FVIII). Interdimeric disulfide linking leads to multimers composed of up to 40 dimers. vWF serves as a carrier of FVIII and is required for normal interactions of platelets with the subendothelium of the injured vessel wall. Von Willebrand factor was purified from human plasma cryoprecipitate and fermentation supernatant of recombinant CHO cells by anion exchange chromatography. Heparin affinity chromatography was used to isolate vWF polymers of different degree of multimerization. Analysis of collagen binding and platelet aggregation revealed that these activities increase with increasing degree of multimerization of vWF. Binding of FVIII to vWF was studied by real-time biospecific interaction analysis and surface plasmon technology. The binding data showed that the binding of FVIII is independent of vWF multimerization. Using recombinant FVIII and recombinant vWF, real-time biospecific interaction analysis resulted in a potential stoichiometry of 2 to 2.5 vWF-subunits per bound FVIII molecule. The kinetic analysis of the vWF-FVIII interaction resulted in a binding rate constant of about 3 x 10(6) M-1 s-1 and an equilibrium dissociation constant of about 0.4 x 10(-9) M.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885147     DOI: 10.1016/0049-3848(96)00161-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  13 in total

1.  The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity.

Authors:  Rens de Groot; David A Lane; James T B Crawley
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

2.  Evaluation of the effect of 6 von Willebrand factor concentrates on platelet adhesion to human vein segments under flow conditions.

Authors:  Wolfgang Mouton; Jerzy Madon; Joerg Fehr; Thomas Bombeli
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

3.  Platelet adhesive dynamics. Part I: characterization of platelet hydrodynamic collisions and wall effects.

Authors:  Nipa A Mody; Michael R King
Journal:  Biophys J       Date:  2008-05-30       Impact factor: 4.033

4.  The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.

Authors:  Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap
Journal:  J Thromb Haemost       Date:  2019-03-19       Impact factor: 5.824

5.  Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice.

Authors:  Q Shi; E L Kuether; J A Schroeder; S A Fahs; R R Montgomery
Journal:  Haemophilia       Date:  2012-01-04       Impact factor: 4.287

6.  Triplet structure of human von Willebrand factor.

Authors:  B E Fischer; K B Thomas; U Schlokat; F Dorner
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

7.  Platelet adhesive dynamics. Part II: high shear-induced transient aggregation via GPIbalpha-vWF-GPIbalpha bridging.

Authors:  Nipa A Mody; Michael R King
Journal:  Biophys J       Date:  2008-05-30       Impact factor: 4.033

Review 8.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

Review 9.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.

Authors:  Marcus Stockschlaeder; Reinhard Schneppenheim; Ulrich Budde
Journal:  Blood Coagul Fibrinolysis       Date:  2014-04       Impact factor: 1.276

10.  Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications.

Authors:  Tosti J Mankelow; Belinda K Singleton; Pedro L Moura; Christian J Stevens-Hernandez; Nicola M Cogan; Gyongyver Gyorffy; Sabine Kupzig; Luned Nichols; Claire Asby; Jennifer Pooley; Gabriella Ruffino; Faroakh Hosseini; Fiona Moghaddas; Marie Attwood; Alan Noel; Alex Cooper; David T Arnold; Fergus Hamilton; Catherine Hyams; Adam Finn; Ashley M Toye; David J Anstee
Journal:  EJHaem       Date:  2021-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.